Dupixent, dupilumab
Named-patient access overview. Dupixent is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
This page is informational, not medical advice. Always work with a licensed treating physician on prescribing decisions.
About Dupixent
Dupixent is the brand name for dupilumab, a fully human monoclonal antibody co-developed by Sanofi and Regeneron. The US Food and Drug Administration first approved Dupixent in March 2017 for adults with moderate-to-severe atopic dermatitis. The label has since expanded materially across allergic and Type 2 inflammatory disease, making Dupixent one of the most broadly indicated biologics on the US market.
Dupixent has become a default first-line biologic in atopic dermatitis and eosinophilic asthma in markets where it is reimbursed. In several Reserve Meds destination countries, however, it is either not on local formulary, not yet locally registered, or available only through programs with multi-month waitlists.
Mechanism of action
Type 2 inflammation is a shared immune pathway behind atopic dermatitis, asthma, nasal polyps, eosinophilic esophagitis, and several other allergic conditions. Two cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13), are central drivers of that pathway. Both signal through a shared receptor subunit called IL-4 receptor alpha, or IL-4Rα.
Dupilumab binds IL-4Rα and blocks signaling from both IL-4 and IL-13 at the same time. In plain terms: it disables 2 of the master switches the immune system uses to keep allergic inflammation running. It does not suppress the immune system the way a steroid or a broad immunosuppressant does, which is part of why patients tolerate it for long stretches.
FDA-approved indications
The current US label covers, in age-appropriate populations: moderate-to-severe atopic dermatitis; add-on maintenance treatment of moderate-to-severe eosinophilic or oral-steroid-dependent asthma; chronic rhinosinusitis with nasal polyps; eosinophilic esophagitis; prurigo nodularis; and chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype. Pediatric approvals run as young as 6 months for atopic dermatitis. Patients should always confirm the current label and age-appropriate indications with their treating physician.
Dosing and administration
Dupixent is administered as a subcutaneous injection from a prefilled syringe or autoinjector pen. Dosing varies materially by indication and patient weight. A common adult atopic-dermatitis regimen is a 600 mg loading dose followed by 300 mg every 2 weeks. Asthma dosing is typically 400 mg loading then 200 mg every 2 weeks, or 600 mg / 300 mg in certain populations. The 200 mg and 300 mg single-dose presentations are designed for at-home self-injection after physician training. Refrigerated storage between 36 and 46 degrees Fahrenheit is required, with limited room-temperature stability.
Side-effect profile
Across indications, the most commonly reported side effects are injection-site reactions and conjunctivitis (eye inflammation, more frequent in the atopic-dermatitis population than the asthma population). Other reported effects include oral herpes reactivation, eosinophilia of unclear clinical significance, and uncommon hypersensitivity reactions. A small subset of asthma patients have experienced eosinophilic conditions consistent with eosinophilic granulomatosis with polyangiitis when oral steroids were tapered too quickly.
Dupixent is not a systemic immunosuppressant in the traditional sense, and routine lab monitoring is not built into the label the way it is for some other biologics. That said, every patient is different, and the right monitoring cadence is a conversation between patient and treating physician.
Why international patients seek Dupixent cross-border
In several countries Reserve Meds serves, Dupixent is locally available only for the narrowest atopic-dermatitis or asthma indications, often after failure of multiple other lines of therapy. Patients with eosinophilic esophagitis, prurigo nodularis, COPD, or pediatric atopic dermatitis frequently find no local pathway at all, despite holding a clear US-label indication and a treating physician's prescription. Named-patient programs and personal-import frameworks exist for exactly this kind of clinically justified, non-substitutable case.
Reserve Meds sources Dupixent from DSCSA-compliant US specialty wholesalers, with full serialization and unbroken cold chain from US warehouse to destination. Every Dupixent case is physician-led, documented, and routed through the destination country's lawful import framework. We do not handle controlled substances. We do not sell direct to consumers.
Start a request for Dupixent
Submit a 60-second intake. Our clinical team will review your case and respond as our first cohort opens with case-specific feasibility, a country pathway, an indicative timeline, and a formal quote. Reserved for you.
Access by country
Reserve Meds publishes a detailed country deep-dive for Dupixent in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.